Our approach

Finding clearer paths to patients

We pursue de-risked assets, including medicines with a clear path to commercialisation or reformulation.

We leverage data mining across scientific literature, global electronic health record data and pharmacy prescription data. Our complex algorithms help us identify highly commercialisable assets that are sufficiently de-risked.

Our team has strong experience in the clinical development of assets, from development strategy all the way through to commercialisation.